Q-omics provides the consensus-scored PNMA6B profile across patient tissues and cancer cell-line models. PNMA6B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PNMA6B is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, PNMA6B RNA expression shows 5,278 significant pathway-activity associations, with the highest sampling consensus in COAD. Together, these results highlight ACC, BRCA, and COAD as cancer lineages where PNMA6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PNMA6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PNMA6B survival associations across molecular data types. PNMA6B RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PNMA6B RNA expression–survival associations across cancer types. High PNMA6B expression shows unfavorable associations in ACC, UCS and PAAD, but favorable associations in BRCA, KIRP and KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PNMA6B RNA expression.
This table summarizes PNMA6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PNMA6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PNMA6B shows lower tumor expression in BRCA and KICH and higher tumor expression in BRCA and LUAD. The BRCA box plot shows higher PNMA6B RNA expression in normal versus tumor tissue (log2 FC = −0.048, t-test p = .022).
This table shows molecular features associated with PNMA6B in patient tissues and cancer cell lines. In patient samples, PNMA6B shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
